企業情報 基盤技術トランスポーターと創薬 開発パイプライン アミノ酸トランスポーター創薬 尿酸トランスポーター創薬 高リン血症治療薬


Greetings
J-Pharma is a Japan based bioventure, who aspires to contribute to the society by developing novel medicines through exploration of the mechanism of onset and exacerbation of human diseases.

Our drug discovery effort targets Transporter proteins, most of which exist as cell membrane proteins. These proteins function as trans-membrane substance transporters, which are crucial to cell’s growth and viability.

While its existence has been known for some time, there are only a few drugs which targets transporters. We believe our research of transporters in normal and pathological conditions will provide new knowledge regarding etiology of diseases with high unmet medical needs, leading to discovery and development of innovative medications.

Our mission at J-Pharma is to build a robust portfolio of drugs and diagnostics based on our pioneering research on transporters, and make them available world-wide for patients in need.
 
Hitoshi Endou, M.D., Ph.D. | Executive Chairman & CEO 
News&Topics
Backnumber
2018/05/23 JPH203 Phase I result will be presented at ASCO Annual Meeting
2018/03/29 Announcement of in-license agreement for a candidate compound of novel anticancer drug which inhibits amino acid transporter-1 (LAT1)
2018/01/19 Completion of Phase I clinical trial of novel anti-cancer agent JPH 203
2017/09/28 Hitoshi Endou, Ph.D. was appointed as Executive Chairman and Takeshi Hirayama was elected as President & CEO
2017/09/11 Joint research agreement with Osaka University on a novel PET probe (NKO 028)
2016/05/10 Granting of uric acid transporter URAT 1 patent to AstraZeneca group
2015/11/24 Certified as "Yokohama Intellectual Property MIRAI Enterprises"
2015/04/20 J-pharma’s licensing strategy regarding our research tool patent
2015/02/17 Announcement of Phase I clinical trial of novel anti-cancer agent JPH 203